Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study

John Busby; Cécile  Holweg; Akiko Chai; Peter Bradding; Fang Cai; Rekha Chaudhuri; Adel Mansur; James Lordan; John G. Matthews; Andrew Menzies-Gow; Rob Niven; Tracy Staton; Liam G Heaney; Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK)

doi:10.1136/thoraxjnl-2018-212709

Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study

John Busby
, Cécile Holweg
, Akiko Chai
, Peter Bradding
, Fang Cai
, Rekha Chaudhuri
, Adel Mansur
, James Lordan
, John G. Matthews
, Andrew Menzies-Gow
, Rob Niven
, Tracy Staton
, Liam G Heaney
, Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK)

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

390 Downloads (Pure)

Abstract

Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a seven-day prednisolone boost (0.5mg/kg). High-dose OCS reduced median blood eosinophils (-60cells/µl; 95% CI: -140, -10), periostin (-8.4ng/ml; -11.6, -2.8), FeNO (-19.0ppb; -28.5, -4.0), IL-5 ( 0.17pg/ml; -0.28, -0.08) and IL-13 (-0.15pg/ml; -0.27, -0.03). There were small improvements in mean FEV1 (0.16L; 0.05, 0.27) and ACQ-7 score (0.3; 0.0, 0.7). Study measures returned to baseline one month post-intervention. Following rescue OCS, one month is sufficient before using type-2 biomarkers to guide long-term treatment.

Original language	English
Pages (from-to)	806-809
Number of pages	4
Journal	Thorax
Volume	74
Issue number	8
Early online date	02 Apr 2019
DOIs	https://doi.org/10.1136/thoraxjnl-2018-212709
Publication status	Published - 15 Jul 2019

Bibliographical note

Keywords

Asthma
Corticosteroid

Access to Document

10.1136/thoraxjnl-2018-212709Licence: Unspecified

Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study
Copyright 2019 the authors. This manuscript is distributed under a Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Accepted author manuscript, 373 KBLicence: CC BY-NC

Cite this

Busby, J., Holweg, C., Chai, A., Bradding, P., Cai, F., Chaudhuri, R., Mansur, A., Lordan, J., Matthews, J. G., Menzies-Gow, A., Niven, R., Staton, T., Heaney, L. G., & Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK) (2019). Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study. Thorax, 74(8), 806-809. https://doi.org/10.1136/thoraxjnl-2018-212709

@article{046a522d290a4ea1ac335e50ec31153f,

title = "Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study",

abstract = "Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a seven-day prednisolone boost (0.5mg/kg). High-dose OCS reduced median blood eosinophils (-60cells/µl; 95\% CI: -140, -10), periostin (-8.4ng/ml; -11.6, -2.8), FeNO (-19.0ppb; -28.5, -4.0), IL-5 ( 0.17pg/ml; -0.28, -0.08) and IL-13 (-0.15pg/ml; -0.27, -0.03). There were small improvements in mean FEV1 (0.16L; 0.05, 0.27) and ACQ-7 score (0.3; 0.0, 0.7). Study measures returned to baseline one month post-intervention. Following rescue OCS, one month is sufficient before using type-2 biomarkers to guide long-term treatment.",

keywords = "Asthma, Corticosteroid",

author = "John Busby and C{\'e}cile Holweg and Akiko Chai and Peter Bradding and Fang Cai and Rekha Chaudhuri and Adel Mansur and James Lordan and Matthews, \{John G.\} and Andrew Menzies-Gow and Rob Niven and Tracy Staton and Heaney, \{Liam G\} and \{Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK)\}",

note = "{\textcopyright} Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2019",

month = jul,

day = "15",

doi = "10.1136/thoraxjnl-2018-212709",

language = "English",

volume = "74",

pages = "806--809",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "8",

}

Busby, J, Holweg, C, Chai, A, Bradding, P, Cai, F, Chaudhuri, R, Mansur, A, Lordan, J, Matthews, JG, Menzies-Gow, A, Niven, R, Staton, T, Heaney, LG & Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK) 2019, 'Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study', Thorax, vol. 74, no. 8, pp. 806-809. https://doi.org/10.1136/thoraxjnl-2018-212709

TY - JOUR

T1 - Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study

AU - Busby, John

AU - Holweg, Cécile

AU - Chai, Akiko

AU - Bradding, Peter

AU - Cai, Fang

AU - Chaudhuri, Rekha

AU - Mansur, Adel

AU - Lordan, James

AU - Matthews, John G.

AU - Menzies-Gow, Andrew

AU - Niven, Rob

AU - Staton, Tracy

AU - Heaney, Liam G

AU - Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK)

PY - 2019/7/15

Y1 - 2019/7/15

N2 - Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a seven-day prednisolone boost (0.5mg/kg). High-dose OCS reduced median blood eosinophils (-60cells/µl; 95% CI: -140, -10), periostin (-8.4ng/ml; -11.6, -2.8), FeNO (-19.0ppb; -28.5, -4.0), IL-5 ( 0.17pg/ml; -0.28, -0.08) and IL-13 (-0.15pg/ml; -0.27, -0.03). There were small improvements in mean FEV1 (0.16L; 0.05, 0.27) and ACQ-7 score (0.3; 0.0, 0.7). Study measures returned to baseline one month post-intervention. Following rescue OCS, one month is sufficient before using type-2 biomarkers to guide long-term treatment.

AB - Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a seven-day prednisolone boost (0.5mg/kg). High-dose OCS reduced median blood eosinophils (-60cells/µl; 95% CI: -140, -10), periostin (-8.4ng/ml; -11.6, -2.8), FeNO (-19.0ppb; -28.5, -4.0), IL-5 ( 0.17pg/ml; -0.28, -0.08) and IL-13 (-0.15pg/ml; -0.27, -0.03). There were small improvements in mean FEV1 (0.16L; 0.05, 0.27) and ACQ-7 score (0.3; 0.0, 0.7). Study measures returned to baseline one month post-intervention. Following rescue OCS, one month is sufficient before using type-2 biomarkers to guide long-term treatment.

KW - Asthma

KW - Corticosteroid

U2 - 10.1136/thoraxjnl-2018-212709

DO - 10.1136/thoraxjnl-2018-212709

M3 - Article

C2 - 30940770

SN - 0040-6376

VL - 74

SP - 806

EP - 809

JO - Thorax

JF - Thorax

IS - 8

ER -

Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this